Toyota Motor's global output increased 11.9 percent on-year to 773,135 vehicles in July, but the growth pace was well below the 41.2 percent gain in June due to the pandemic and a global semiconductor shortage.
While the output growth was for the 11th straight month, the carmaker is expecting a production cut of 40 percent or some 360,000 units in September due to pandemic-caused difficulties in securing components in Southeast Asia, where many suppliers are based.
In Japan, Toyota manufactured 309,138 units, up 21.8 percent.
Toyota's overseas production surged 6.1 percent to 463,997 vehicles, with those from China and other Asian countries increasing 9.1 percent.
In North America, Toyota's production dipped 2.4 percent.
With an increased demand for vehicles in key overseas markets, including North America, Toyota increased sales for the 11th straight month 858,569 vehicles, which is the largest figure for July.


Asian Currencies Weaken as Dollar Rebounds Amid Middle East Escalation
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Trump Claims Iran Sought Ceasefire as Middle East War Escalates
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
South Korea's Inflation Rises Modestly in March Amid Oil Price Pressures
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Bank of America's $72.5M Epstein Settlement: What You Need to Know
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Japan Business Sentiment Rises as Iran War Fuels Inflation Fears, BOJ Rate Hike Looms
Trump's Iran War Speech Sparks Market Anxiety Over Extended Conflict
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



